Brazil deaths prompt withdrawal of Enila contrast agents
This article was originally published in Clinica
Executive Summary
The Brazilian healthcare surveillance agency, Anvisa, last week withdrew the contrast agent, Celobar, after it was linked to several deaths and almost one hundred adverse events in patients undergoing radiological examination. The product is made by Rio de Janeiro-based Enila Industria e Comercio de Produtos Quimicos e Farmaceuticos (Enila).